Hjem › Neuroblastom
Neuroblastom kliniske forsøg rekrutterer i USA
47 studier for Neuroblastom rekrutterer deltagere på steder over hele USA.
Byer med flest studier
- Boston, MA13 studier
- Washington, DC11 studier
- New York City, NY10 studier
- Philadelphia, PA9 studier
- Dallas, TX9 studier
- Memphis, TN9 studier
- St. Louis, MO9 studier
- Aurora, CO8 studier
- Hartford, CT8 studier
- Minneapolis, MN8 studier
- Birmingham, AL8 studier
- Atlanta, GA7 studier
- Los Angeles, CA7 studier
- San Francisco, CA7 studier
- Cincinnati, OH7 studier
- Houston, TX7 studier
- Orlando, FL7 studier
- Miami, FL7 studier
- Chicago, IL6 studier
- Seattle, WA6 studier
- Durham, NC6 studier
- Salt Lake City, UT6 studier
- Portland, OR6 studier
- Little Rock, AR6 studier
- Honolulu, HI6 studier
- Greenburgh, NY6 studier
- Gainesville, FL6 studier
- Harrisburg, PA6 studier
- Columbus, OH5 studier
- Ann Arbor, MI5 studier
- Mountain View, CA5 studier
- Nashville, TN5 studier
- San Diego, CA5 studier
- Oakland, CA5 studier
- Austin, TX5 studier
- Fort Worth, TX4 studier
- Madison, WI4 studier
- Edison, NJ4 studier
- Clifton, NJ4 studier
- Charlotte, NC4 studier
Efter delstat
- Alabama8 studier
- Arizona3 studier
- Arkansas6 studier
- Californien14 studier
- Colorado8 studier
- Connecticut9 studier
- District of Columbia6 studier
- Florida9 studier
- Georgia9 studier
- Hawaii6 studier
- Illinois6 studier
- Indiana3 studier
- Iowa3 studier
- Kentucky5 studier
- Maryland8 studier
- Massachusetts13 studier
- Michigan8 studier
- Minnesota9 studier
- Missouri10 studier
- New Jersey6 studier
- New York13 studier
- North Carolina7 studier
- North Dakota3 studier
- Ohio8 studier
- Oregon6 studier
- Pennsylvania14 studier
- Rhode Island3 studier
- South Carolina4 studier
- South Dakota3 studier
- Tennessee12 studier
- Texas15 studier
- Utah6 studier
- Virginia3 studier
- Washington6 studier
- Wisconsin4 studier
Nyligt opdaterede studier
Officiel studietekst (engelsk)
Dinutuximab With Chemotherapy, Surgery and Stem Cell Transplantation for the Treatment of Children With Newly Diagnosed High Risk Neuroblastoma
RekruttererFase 3
Op til 30 år · Alle køn · Opdateret 2. okt. 2026 · NCT06172296Comprehensive Omics Analysis of Pediatric and Adult Solid Tumors and Establishment of a Repository for Related Biological Studies
RekruttererObservationsstudieFrivillige med god helbredstilstand velkomne
4 Weeks · Alle køn · Opdateret 2. okt. 2026 · NCT01109394MCT for the Harvard/UCSF ROBIN Center
Rekrutterer
Alle aldre · Alle køn · Opdateret 1. okt. 2026 · NCT06000787A Study of a Vaccine in Combination With β-glucan and GM-CSF in People With Neuroblastoma
RekruttererFase 2Frivillige med god helbredstilstand velkomne
Alle aldre · Alle køn · Opdateret 30. sep. 2026 · NCT04936529Phase I Trial of rhIL-15 Plus Dinutuximab Plus Irinotecan/Temozolomide for Children and Young Adults With Relapsed/Refractory Neuroblastoma
RekruttererFase 1
Alder 3 til 35 · Alle køn · Opdateret 24. sep. 2026 · NCT06995872Prospective Comprehensive Molecular Analysis of Endocrine Neoplasms
RekruttererObservationsstudie
Alder 4 og opefter · Alle køn · Opdateret 22. sep. 2026 · NCT01005654Substudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01A/LIGHTBEAM-U01)
RekruttererFase 1/2
6 Months – 25 Years · Alle køn · Opdateret 17. sep. 2026 · NCT06395103Biomarkers of Resiliency In Childhood Cancer Surgery
RekruttererObservationsstudie
Alder 3 til 25 · Alle køn · Opdateret 14. sep. 2026 · NCT06674811Pediatric Precision Laboratory Advanced Neuroblastoma Therapy
RekruttererFase 2
Op til 22 år · Alle køn · Opdateret 4. sep. 2026 · NCT02559778Eflornithine (DFMO) and AMXT 1501 for Neuroblastoma, CNS Tumors, and Sarcomas
RekruttererFase 1/2
Op til 26 år · Alle køn · Opdateret 3. sep. 2026 · NCT06465199Silmitasertib (CX-4945) in Combination With Chemotherapy for Relapsed Refractory Solid Tumors
RekruttererFase 1/2
Op til 30 år · Alle køn · Opdateret 3. sep. 2026 · NCT06541262B7-H3.CD28Z.CART in Solid Tumors
RekruttererFase 1
9 Months – 30 Years · Alle køn · Opdateret 3. sep. 2026 · NCT07358260Tipifarnib and Naxitamab for Relapsed/Refractory Neuroblastoma
RekruttererFase 2
Alder 1 til 21 · Alle køn · Opdateret 3. sep. 2026 · NCT06540963International Congenital Central Hypoventilation Syndrome (CCHS) Registry and CCHS SHARE
RekruttererObservationsstudie
Alle aldre · Alle køn · Opdateret 3. sep. 2026 · NCT03088020N10: A Study of Reduced Chemotherapy and Monoclonal Antibody (mAb)-Based Therapy in Children With Neuroblastoma
RekruttererFase 2
18 Months – 19 Years · Alle køn · Opdateret 28. aug. 2026 · NCT06528496Testing the Addition of 131I-MIBG or Lorlatinib to Intensive Therapy in People With High-Risk Neuroblastoma (NBL)
RekruttererFase 3
365 Days – 30 Years · Alle køn · Opdateret 25. aug. 2026 · NCT03126916Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors
RekruttererFase 1/2
12 Months – 30 Years · Alle køn · Opdateret 25. aug. 2026 · NCT04851119Haploidentical Donor Cytokine-Induced Memory-Like Natural Killer Cells (CIML-NK) for Relapsed & Refractory Neuroblastoma
RekruttererFase 2
Alder 1 til 39 · Alle køn · Opdateret 24. aug. 2026 · NCT07635056Selective Antigen Specific T Cells and CAR T Cells in Subjects With Relapsed/Refractory Embryonal Tumors (SABRE)
RekruttererFase 1
Alder 1 til 23 · Alle køn · Opdateret 13. aug. 2026 · NCT07172958Naxitamab Added to Induction for Newly Diagnosed High-Risk Neuroblastoma
RekruttererFase 2
12 Months – 21 Years · Alle køn · Opdateret 12. aug. 2026 · NCT05489887SPEARHEAD-3 Pediatric Study
RekruttererFase 1/2
Alder 2 til 21 · Alle køn · Opdateret 11. aug. 2026 · NCT05642455A Study of a Vaccine in Combination With Beta-glucan in People With Neuroblastoma
RekruttererFase 2
Alle aldre · Alle køn · Opdateret 28. jul. 2026 · NCT06057948PEEL-224, Vincristine and Temozolomide in Pediatric Solid Tumors
RekruttererFase 1/2
Alder 1 til 30 · Alle køn · Opdateret 22. jul. 2026 · NCT06721689NKG2D.Zeta-NK Cell Conditioning With C7R.GD2.CAR-T Cells for Patients With Relapsed or Refractory Osteosarcoma or Neuroblastoma
RekruttererFase 1
Alder 1 til 24 · Alle køn · Opdateret 21. jul. 2026 · NCT07211737NANT 2021-01 Phase II STING (Sequential Temozolomide, Irinotecan, NK Cells and GD2 mAb) Trial
RekruttererFase 2
Alder 1 til 31 · Alle køn · Opdateret 20. jul. 2026 · NCT06450041Fra ClinicalTrials.gov, data hentet 3. okt. 2026. Hver studie har sine egne kvalifikationskrav; studieteamet afgør, hvem der kan deltage.